Exicure, Inc. reports the full year 2024 financial results

Chicago (Business Wire) -exicure, Inc. (Nasdaq: XCUR) in the past was a biotechnology company in the early stages that focuses on the development of nucleic acid therapies for ribonucleic acid against validated goals. In September 2022, the company announced a significant reduction in strength, the suspension of preclinical activities and the cessation of all research and development and the company examined strategic alternatives to maximize the shareholder value. We continue to carry out a broader research of strategic alternatives. These efforts include researching growth through transactions with potential partners who are agreed with an existing, listed organization.

2024 financial results

Cash position: As of December 31, 2024, cash and cash equivalents amounted to USD $ 0.8 million on December 31, 2023. Our current liquidity may not be sufficient to finance the operation for the next 12 months. Additional financing will be necessary to finance our ongoing operations and research into strategic alternatives and to pursue all alternatives identified by us.

Research and development effort (F&E): The research and development costs amounted to 0 USD for the financial year ending on December 31, 2024 compared to USD 1.4 million for the financial year that ended on December 31, 2023. As a result, the company found that after the first quarter of 2023 it was no longer appropriate to record research and development costs.

General and administrative (G&A) cost: General and Administrative Expenses Were $ 5.4 Million for the Year Ended December 31, 2024, as Compared to $ 11.7 Million for the Year Ended December 31, 2023. The Decree in G&A Expense Of $ 6.3 Million for the Year Ended December 31, 2024 Was Due to Higher Costs in 2023 from Separation PAY OF Former Executives and Related Stock Compensation Expense, Payroll and Related Benefits, Legal and Consulting Fe, Facility and Lease Costs, the depreciation of the assets sold as well as research and development will no longer be classified as research and development due to the shift of our historical operations that are previously discussed, as before Criteria more fulfilled.

Legal disputes of legal costs: The increase of $ 0.6 million for the financial year, which ended on December 31, 2024, was due to the insured and legal defense costs in connection with the legal sentence in connection with the dissatisfied retention and legal defense costs.

Other income: In the second quarter, the company sold samples of its clinical products to a biopharmaceutical company of the private clinical level and sold certain assets in accordance with the purchase contract for assets. The buyer acquired the historical biotechnological intellectual property and other assets of the company and includes spherical nucleic acid-related technology, research and development programs as well as clinical assets.

Net lust: The Company Had a Net Loss of $ (9.7) Million for the Year Ended December 31, 2024, as Compared to A Net Loss of $ 16.9 Million for the Year Ended December 31, 2023. The Decreate in Net Loss of $ 7.2 Million was due to Lower Operating (G&A) Expenses as well as some Revenues and Other Income Earned in 2024, partial offset by the right-of-soet asset impairment Loss Result from the impairing analysis of the the existing assets of the company in connection with its office duct agreement.

Considering concerns: Management is of the opinion that the company's existing cash and cash equivalents may not be sufficient to finance the company. As a result, there is considerable doubts about our ability to deal as an occasion. Additional financing will be necessary to finance our ongoing operations and research into strategic alternatives and to pursue all alternatives identified by us. It cannot be guaranteed that such additional financing can be available and, if available, can be made on acceptable conditions.

About illuminating

In the past, Exicure, Inc. was an early stage in the past that focuses on the development of nucleic acid therapies for ribonucleic acid against validated goals. After its recent restructuring and suspension of clinical and development activities, the company examines strategic alternatives in order to maximize the shareholder value in terms of its historical biotechnology value and more general. You can find more information at www.exicuretx.com.

Predicted statements

This press release contains future -oriented statements in the sense of the law on private Securities Litigation Reform of 1995. All statements in this press release as statements of historical facts can be regarded as correct, including but not limited to say: statement: the current business plans and the goals of the company. Words such as “plans”, “expected”, “Will”, “anticipated”, “further”, “progress”, “believes”, “goal”, “may”, “intend”, “could” and other words and conditions of similar importance and expression to identify future -oriented statements, although not all future -oriented statements. Future -oriented statements are based on the current beliefs and assumptions of management, which are subject to risks and uncertainties and are not guarantees for future performance. For a discussion of other risks and uncertainties and other important factors, from which the actual results of the company can distinguish from the statements contained in the future statements, see the section entitled “Risk Factors” in the annual report of the company on the forms of 10-K for the year 2023. To update this information or to publicly announced the results of revisions to such statements in order to reflect future events or developments, unless this is required by law.

Contacts

Media contact:
Josh Miller
847-673-1700
media@exicuretx.com